Bladder Cancer Incidence Trends in the United States From 2000 to 2020.

BACKGROUND: Bladder cancer is one of the most common urogenital cancers globally. Here, we aimed to report the incidence trend of bladder cancer in the United States (US) over 2000-2020, by age, sex, race/ethnicity, and types using Surveillance, Epidemiology, and End Results (SEER). METHODS: We used SEER 22 data to calculate the age-standardized and delay-adjustment incidence rate of bladder cancer. Only individuals diagnosed with cancer and whose age at diagnosis was known were included in the study. A delay model was applied, adjusting for variables such as cancer site, registry, age group, race/ethnicity, and year of diagnosis. Using the Tiwari technique, the same database was also used to determine the age-standardized incidence rate (ASIR) of subtypes. The incidence data for 2020 were excluded from Joinpoint trends while displayed separately in illustrations. RESULTS: Over 2000-2019, most bladder cancer cases were urothelial carcinoma (92.99%), among non-Hispanic Whites (84.48%) and those aged 70 to 84 years (45.72%). There was a significant decrease in the ASIR of bladder cancer across all races/ethnicities in both sexes within all age groups (Average annual percent change (AAPC): -0.95%; -1.06, -0.83 for men and -1.02% -1.21, -0.84 for women) over 2000-2019. The incidence rates decreased by 6.23% during the COVID-19 pandemic. Also, the delay-adjusted incidence rate of bladder cancer increased with advancing age. CONCLUSIONS: Despite a decrease in ASIR of bladder cancer over 2000-2019, there are still a high number of incident cases, particularly among NHWs and the elderly. Future studies should investigate the underlying causes of bladder cancer incidence trends among demographic groups.